Quanterix reported Q4 2025 revenue of USD 43.9 million, up 25.0%, with GAAP gross margin of 45.7% and adjusted gross margin of 50.0%. Q4 2025 net loss was USD 23.1 million and adjusted EBITDA loss was USD 7.9 million. Quanterix ended Q4 2025 with USD 121.6 million in cash, cash equivalents, marketable securities and restricted cash, and reported Q4 2025 adjusted cash usage of USD 3.0 million. For FY 2025, Quanterix posted revenue of USD 138.9 million, up 1.0%, with GAAP gross margin of 46.8% and adjusted gross margin of 47.3%. FY 2025 net loss was USD 107.2 million and adjusted EBITDA loss was USD 44.9 million; adjusted cash usage was USD 30.9 million. On the business side, Quanterix said it submitted a 510(k) premarket notification to the FDA in January 2026 for its multi-analyte algorithmic blood test for Alzheimer’s disease, and noted that CMS established a reimbursement rate of USD 897 for its LucentAD Complete test. The company also said it has implemented USD 74 million of cost savings related to its Akoya transaction, with 94% of integration milestones complete and remaining cost synergies expected by the end of Q1 2026. Quanterix added that it launched 13 new assays in 2025, including Simoa tau assays pTau 205 and pTau 212, and two Phenocode Discovery panels in Q4 2025. For 2026, Quanterix guided for revenue of USD 169 million to USD 174 million and said it expects to achieve cash flow breakeven performance in the second half of 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quanterix Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202603021601BIZWIRE_USPR_____20260302_BW510113) on March 02, 2026, and is solely responsible for the information contained therein.
Comments